Posted 9/18/2023, 7:33:35 PM
Moderna Stock Drops as COVID Booster Demand Dwindles; Company Pivots to Oncology and Rare Diseases
- Moderna stock plunges as COVID-19 booster market shrinks to just 24% of eligible Americans
- Analysts project Moderna's COVID-19 sales will level off after 2024 as demand wanes
- Moderna expanding beyond COVID-19 into oncology, rare diseases and other areas
- Cash from COVID-19 sales gives Moderna runway for developing new products
- Analysts forecast 59.67% upside for Moderna stock with $166.25 average price target